36
Participants
Start Date
May 31, 2022
Primary Completion Date
July 6, 2023
Study Completion Date
July 6, 2023
Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection
Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
New York-Presbyterian Hospital/Weill Cornell Medical Center, New York
Tallahassee Research Institute, Tallahassee
Clearwater Cardiovascular Consultants, Clearwater
Vanderbilt University Medical Center, Nashville
The Stern Cardiovascular Foundation, Germantown
Policlinico Sant Orsola - Malpighi, Bologna
The Valley Hospital, Ridgewood
Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec
Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool
Medtronic Cardiac Rhythm and Heart Failure
INDUSTRY